

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

*(use as many sheets as necessary)*

Sheet

of

*Complete if Known*

|                        |                       |
|------------------------|-----------------------|
| Application Number     | 09/668,555            |
| Filing Date            | 9/22/2000             |
| First Named Inventor   | van Oosterhout et al. |
| Group Art Unit         | 1644                  |
| Examiner Name          | R. B. Schwadron       |
| Attorney Docket Number | 2183-4541 US          |

#### **OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

| Examiner Initials * | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T <sup>2</sup> |
|---------------------|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|
| (B)                 |                       | Ypke et al., A combination of anti-CD3 and anti-CD7 ricin A-immunotoxins for the in vivo treatment of acute graft versus host disease, Clinical Observations, Interventions, and Therapeutic Trials, June 15, 2000, pp. 3693-701, Vol. 95, No. 12.              |                |
|                     |                       |                                                                                                                                                                                                                                                                 |                |
|                     |                       |                                                                                                                                                                                                                                                                 |                |
|                     |                       |                                                                                                                                                                                                                                                                 |                |
|                     |                       |                                                                                                                                                                                                                                                                 |                |
|                     |                       |                                                                                                                                                                                                                                                                 |                |
|                     |                       |                                                                                                                                                                                                                                                                 |                |
|                     |                       |                                                                                                                                                                                                                                                                 |                |
|                     |                       |                                                                                                                                                                                                                                                                 |                |
|                     |                       |                                                                                                                                                                                                                                                                 |                |
|                     |                       |                                                                                                                                                                                                                                                                 |                |
|                     |                       |                                                                                                                                                                                                                                                                 |                |
|                     |                       |                                                                                                                                                                                                                                                                 |                |
|                     |                       |                                                                                                                                                                                                                                                                 |                |

|                       |                                                                                     |                    |            |
|-----------------------|-------------------------------------------------------------------------------------|--------------------|------------|
| Examiner<br>Signature |  | Date<br>Considered | 10/17/2001 |
|-----------------------|-------------------------------------------------------------------------------------|--------------------|------------|

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.